(Q24240433)

8

0 references

Christine Rummel-Kluge

2

0 references

Katja Komossa

1

0 references

author name string

Katja Komossa

1

0 references

Heike Hunger

3

0 references

Franziska Schmid

4

0 references

Sandra Schwarz

5

0 references

Joaquim I Silveira da Mota Neto

Cochrane Database of Systematic Reviews

6

0 references

language of work or name

English

0 references

publication date

2010

0 references

published in

0 references

issue

1

0 references

page(s)

CD006624

0 references

cites work

Olanzapine for schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Aripiprazole for schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Imputing missing standard deviations in meta-analyses can provide accurate results

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Meta-analyses involving cross-over trials: methodological issues

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Detecting skewness from summary information

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Second generation antipsychotics improve sexual dysfunction in schizophrenia: a randomised controlled trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Schizophrenia and employment - a review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Issues in the meta-analysis of cluster randomized trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Amisulpride for schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Statistics notes. Trials randomised in clusters

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Treatment programme and long-term outcome in chronic schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

The unit of analysis error in studies about physicians' patient care behavior

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Revising axis V for DSM-IV: a review of measures of social functioning

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Clinical update on amisulpride in deficit schizophrenia.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

A rating scale for extrapyramidal side effects

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Aripiprazole for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Treatment of depression in first episode of schizophrenia: results from EUFEST.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164462

Sexual Dysfunction in First-Episode Schizophrenia Patients

29 November 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

21 January 2018

1 reference

12 December 2020

[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]

1 reference

12 December 2020

[Current assessment of new/atypical neuroleptic agents]

1 reference

12 December 2020

Neurocognitive performance in first-episode and chronic schizophrenic patients

1 reference

12 December 2020

Congratulations to Mike Startup and colleagues (Startup et al. 2004) for their excellent study replicating and extending our initial trial applying CBT to promote recovery from acute psychosis (Drury et al. 1996a,b, 2001)

1 reference

12 December 2020

Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study

1 reference

12 December 2020

Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial

1 reference

12 December 2020

Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics

1 reference

12 December 2020

Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.

1 reference

12 December 2020

Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality

1 reference

12 December 2020

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

12 December 2020

1 reference

12 December 2020

LARGE EFFECT OF BASELINE TREATMENT WITH LONG ACTING ANTIPSYCHOTIC DRUGS ON RANDOMIZED TREATMENT OUTCOMES

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006624.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD006624.PUB2

1 reference

1 reference

1 reference

PubMed publication ID

20091599

1 reference